Lexicon Pharma (LXRX) Tops Q1 EPS by 5c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.03 -5.58%
Revenue Growth %: -78.9%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -78.9%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.07), $0.05 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $1.26 million versus the consensus estimate of $2.82 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Iran Has Resumed Producing Ballistic Missiles, U.S. and Middle East Officials Say - WSJ
- United Rentals (URI) call put ratio 1 call to 2.8 puts as share price down 4%
- Gentherm shareholders back Modine unit merger, close set for Oct. 1
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
